Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Short term Debt (2020 - 2021)

Rein Therapeutics filings provide 2 years of Short term Debt readings, the most recent being $329000.0 for Q1 2021.

  • For the quarter ending Q1 2021, Short term Debt changed N/A year-over-year to $329000.0, compared with a TTM value of $329000.0 through Mar 2021, changed N/A, and an annual FY2020 reading of $168000.0, changed N/A over the prior year.
  • Short term Debt hit $329000.0 in Q1 2021 for Rein Therapeutics, up from $168000.0 in the prior quarter.
  • The five-year high for Short term Debt was $329000.0 in Q1 2021, with the low at $48000.0 in Q3 2020.